IDIBAPS, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Resultats de l'any: 2010 2009 2008 2007

Articles de l'any 2010

• Retransplantation in patients with hepatitis C recurrence after liver transplantation

  Carrion JA, Navasa M, Forns X
  J HEPATOL. 2010; 53: 962-970. IF: 7.818

• ATG-Fresenius Treatment and Low-Dose Tacrolimus: Results of a Randomized Controlled Trial in Liver Transplantation

  Benitez CE, Puig-Pey I, Lopez M, Martinez-Llordella M, Lozano JJ, Bohne F, Londono MC, Garcia-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sanchez-Fueyo A
  AM J TRANSPLANT. 2010; 10: 2296-2304. IF: 6.433

• Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

  Morales JM, Campistol JM, Dominguez-Gil B, Andres A, Esforzado N, Oppenheimer F, Castellano G, Fuertes A, Bruguera M, Praga M
  AM J TRANSPLANT. 2010; 10: 2453-2462. IF: 6.433

• Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response

  Fernandez-Rodriguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincon D, Rodriguez-Caravaca G, Barcena R, Serra MA, Romero-Gomez M, Fernandez I, Garcia-Samaniego J, Fuente J, Sola R, Moreno-Otero R, Planas R
  AM J GASTROENTEROL. 2010; 105: 2164-2172. IF: 6.012

• Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI (R)

  Vilaplana C, Montane E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J
  VACCINE. 2010; 28: 1106-1116. IF: 3.616

• Treating hepatitis C in patients with cirrhosis: The effort is worth it

  Forns X, Bruix J
  J HEPATOL. 2010; 52: 624-626. IF: 7.818

• Multifaceted Perspective of the Waiting List for Liver Transplantation: The Value of Pharmacokinetic Models

  Navasa M, Bruix J
  HEPATOLOGY. 2010; 51: 12-15. IF: 10.84

• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

  Kwo PY, Lawitz EJ, Mccone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK
  LANCET. 2010; 376: 705-716. IF: 30.758

• Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1

  Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, Mchutchison JG
  GASTROENTEROLOGY. 2010; 139: 1257-1266. IF: 12.899

• EASL Clinical Practice Guidelines: Management of chronic hepatitis B

  Forns X, Et AL
  J HEPATOL. 2010; 50: 227-242. IF: 7.818

Més articles

Tesis

• Estudio de la evolución genética y la compartimentalización del virus de la hepatitis C

  Doctorand: Santseharay Ramirez Almeida,
  Director/s: Forns X

• Tratamiento de la hepatitis crónica C antes y despues del trasplante Hepático(TH) y diagnóstico no invasivo de su recurrencia tras el TH

  Doctorand: Jose Antonio Carrion Rodriguez,
  Director/s: Forns X